How did Vericel's revenue and expenses trend in Q4 2024?

Vericel's revenue and expenses in Q4 2024 showed a business-focused trend, with the company's net income standing at $19.81 million. The total operating expenses were $38.61 million, which were primarily attributed to the third-generation autologous chondrocyte implantation product. The revenue by segment for this product was $197.31 million, indicating a strong performance. Additionally, Vericel had a revenue of $128.97 million from the Epicel product and $36.62 million from the Nexobrid product. The company's financial performance in Q4 2024 reflects a solid business strategy with significant revenue generation and effective expense management.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|VCEL|VCEL.O|Vericel|20240101-2024|Nexobrid|3292000|185|
|VCEL|VCEL.O|Vericel|20240101-2024|Nexobrid|2269000|185|
|VCEL|VCEL.O|Vericel|20240101-2024|Nexobrid|1205000|185|
|VCEL|VCEL.O|Vericel|20240101-2024|Nexobrid|436000|185|
|VCEL|VCEL.O|Vericel|20240101-2024|Epicel|1.0664E7|185|
|VCEL|VCEL.O|Vericel|20240101-2024|Third-generation autologous chondrocyte implantation product|4.0181E7|185|
|VCEL|VCEL.O|Vericel|20240101-2024|Nexobrid|436000|185|

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|VCEL|VCEL.O|Vericel|2024 Q1|48.47231487658439|-3862000|185|
|VCEL|VCEL.O|Vericel|2024 Q2|6.733067729083666|-4682000|185|
|VCEL|VCEL.O|Vericel|2024 Q3|75.38251366120218|-901000|185|
|VCEL|VCEL.O|Vericel|2024 Q4|52.44362348957131|1.9807E7|185|

|code|Ticker|Name|Date|Gross PP&E YoY|Gross PP&E|market_code|
|---|---|---|---|---|---|---|
|VCEL|VCEL.O|Vericel|20240331|113.42816652851681|7.982E7|185|
|VCEL|VCEL.O|Vericel|20240630|123.91573445809647|9.7681E7|185|
|VCEL|VCEL.O|Vericel|20240930|121.64300991639121|1.13991E8|185|
|VCEL|VCEL.O|Vericel|20241231|103.72487899625634|1.3006E8|185|